Drugs / OPT101
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06669403 | Dec 2025 → Apr 2026 overdue | infectious disease with sepsis, pneumonia | Op-T LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05428943 | Sep 2022 → Feb 2024 | type 1 diabetes mellitus | Op-T LLC | Completed | No outcome recorded |
| Phase 1 | NCT04589403 | Feb → Sep 2021 | — | Op-T LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06964087 | Apr → May 2026 overdue | type 1 diabetes mellitus | Op-T LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPT101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04589403 ↗ |
| Modality | Peptide | “15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40” NCT04589403 ↗ |
| Route | Intravenous | “administered by a slow IV infusion” NCT04589403 ↗ |
| Target | CD40 | “15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40” NCT04589403 ↗ |